The National Institute for Health and Clinical Excellence (NICE) has recommended erlotinib, an epidermal growth factor receptor inhibitor, as an alternative to docetaxel as a second-line treatment option for patients with non-small-cell lung cancer (NSCLC) provided the manufacturer (Roche) supplies erlotinib...
NICE Approves Lung-Cancer Drug Provided Manufacturer Roche Offers Discounted Price For NHS, UK
Amgen, Takeda And Millennium Provide Update On Phase 3 Trial Of Motesanib In Patients With Non Small Cell Lung Cancer
Amgen (Nasdaq: AMGN) and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited (TSE: 4052), announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced...
First Pivotal Trials Begin For Boehringer Ingelheim’s Novel Triple Angiokinase Inhibitor Vargatef™ (BIBF 1120)
Boehringer Ingelheim has marked a new milestone within its rapidly expanding oncology portfolio with the announcement today that the company has progressed another of its oncology compounds into pivotal phase III clinical development. The two studies, known as LUME-Lung 1 and LUME-Lung 2, for Vargatef™...
EntreMed’s MKC-1 Meets Primary Efficacy Endpoint In Non-Small Cell Lung Cancer Clinical Trial
EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced that it has met the primary endpoint for the efficacy portion of the open label Phase 1/2 study of MKC-1 in combination with pemetrexed (Alimta(R))...
Phase III Study (SATURN) Showed Tarceva Improved Progression-Free Survival As A First-Line Maintenance Therapy For Advanced Non-Small Cell Lung Cancer
Genentech, Inc., (NYSE: DNA) and OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced that a global Phase III study (SATURN) met its primary endpoint and showed Tarceva® (erlotinib) significantly extended the time patients with advanced non-small cell lung cancer (NSCLC) lived without their cancer getting...
Tarceva Brings New Hope To Patients With Advanced Non Small Cell Lung Cancer
Roche announced that the SATURN (SequentiAl Tarceva in UnResectable NSCLC) study met its primary endpoint of progression free survival. The study showed that Tarceva (erlotinib), when given in first line maintenance - immediately following initial treatment with platinum-based chemotherapy - , significantly...
Lung Cancer - Early Detection Saves Lives, Isle Of Wight NHS Primary Care Trust, UK
If you have a cough that won’t go away, feel out of breath and more tired than normal or have lost weight but don’t know why - see your doctor straight away as it could be the early signs of lung cancer. November is Lung Cancer Awareness Month and the aim of this year’s campaign is...
Should Metastasectomy Be Performed Before Other Treatments?
Primary HCC is a major cancer related to HBV viral infection in Asian countries, including Japan. Recently, the primary liver cancers are successfully treated by surgical resection including liver transplantation and non-surgical locoregional therapy. Although infrequently, extrahepatic spread to the...
Scientists Find New Genes Linked To Lung Cancer
Working as part of a multi-institutional collaboration, scientists at Washington University School of Medicine in St. Louis have assembled the most complete catalog to date of the genetic changes underlying the most common form of lung cancer. The research, published Oct. 23 in Nature, helps lay the...
Landmark Genomic Study Of Lung Cancer Published In Nature
Scientists announced the results of the largest genomic study to date of lung adenocarcinoma, the most common form of lung cancer. Led by researchers from the Broad Institute of Harvard and MIT, Dana-Farber Cancer Institute, and other research institutions nationwide, the collaborative study unearthed...